XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 123 filers reported holding XENON PHARMACEUTICALS INC in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2021 | $5,311,000 | +104.4% | 170,000 | 0.0% | 0.17% | +116.7% |
| Q3 2021 | $2,598,000 | -17.9% | 170,000 | 0.0% | 0.08% | -18.8% |
| Q2 2021 | $3,165,000 | +4.0% | 170,000 | 0.0% | 0.10% | 0.0% |
| Q1 2021 | $3,043,000 | +16.4% | 170,000 | 0.0% | 0.10% | +7.9% |
| Q4 2020 | $2,615,000 | +38.9% | 170,000 | 0.0% | 0.09% | +15.6% |
| Q3 2020 | $1,882,000 | -11.7% | 170,000 | 0.0% | 0.08% | -17.2% |
| Q2 2020 | $2,132,000 | +10.6% | 170,000 | 0.0% | 0.09% | -12.3% |
| Q1 2020 | $1,928,000 | -18.3% | 170,000 | -5.6% | 0.11% | +7.1% |
| Q4 2019 | $2,360,000 | +45.5% | 180,000 | 0.0% | 0.10% | +41.4% |
| Q3 2019 | $1,622,000 | -8.6% | 180,000 | 0.0% | 0.07% | -14.6% |
| Q2 2019 | $1,775,000 | +9.2% | 180,000 | +12.5% | 0.08% | +9.3% |
| Q1 2019 | $1,626,000 | +71.7% | 160,000 | +6.7% | 0.08% | +66.7% |
| Q4 2018 | $947,000 | -40.2% | 150,000 | +25.0% | 0.04% | -37.5% |
| Q3 2018 | $1,584,000 | – | 120,000 | – | 0.07% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |